AdBio partners

Cephagenix is a biopharmaceutical company dedicated to discovering and developing innovative therapies for migraine. It specializes in identifying and advancing selective inhibitors of the adenosine triphosphate-sensitive potassium channel subtype expressed in intracranial arteries, which have shown promise in preclinical migraine models. The company's mission is to address the underlying mechanisms of migraine, aiming to provide effective treatments for individuals suffering from this debilitating condition.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Orikine Bio is an innovative biotechnology company focused on developing tailored cytokine-based therapies for the treatment of autoimmune and inflammatory diseases. The company utilizes a proprietary platform to engineer cytokines with unique biological properties, aiming to provide transformative treatment options for patients suffering from immune-mediated disorders. By advancing the field of engineered cytokines, Orikine Bio seeks to create therapies that have the potential to significantly improve patient outcomes and enhance overall quality of life.

Astraveus is a pioneering company specializing in the manufacture of Cell & Gene Therapies (CGTs). It operates the Lakhesys™ platform, an innovative end-to-end solution that optimizes CGT production using single-use microfluidic bioprocessors. This approach reduces infrastructure requirements, lowers costs, and mitigates logistical challenges, aiming to enhance patient access to life-changing therapies while minimizing environmental impact.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with research facilities in Nice. Founded in 2019, it specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of both Type 1 and Type 2 diabetes. The company aims to create a candidate molecule that regenerates pancreatic insulin-producing cells, which could significantly improve the quality of life and survival rates for individuals with diabetes. This innovative approach has the potential to become a groundbreaking therapy for beta-cell regeneration in diabetes management, stemming from research conducted in the laboratory of Dr. Patrick Collombat.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Calida Therapeutics is a biotechnology company focused on developing monoclonal antibodies to treat and prevent thrombo-inflammatory disorders and vascular diseases. The company aims to address the critical connection between thrombosis and inflammation by disrupting the interaction between platelets and myeloid cells. This innovative approach is designed to help patients avoid tissue damage and life-threatening complications associated with these conditions. Through its research and development efforts, Calida Therapeutics seeks to improve treatment options for individuals affected by thrombo-inflammatory disorders.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer. The firm focuses on creating a pipeline of small molecules that specifically target the eukaryotic translation initiation factor-4A to address resistance in patients who have become unresponsive to existing targeted therapies. With a primary emphasis on melanoma, Ribonexus aims to enhance the effectiveness of current treatments by restoring sensitivity to them in patients whose cancers have developed resistance. Through its research and development efforts, Ribonexus seeks to contribute meaningful advancements in oncology and improve treatment outcomes for patients facing challenging cancer types.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in inflammation resolution, aiming to inhibit specific processes in the early stages of inflammation and the recruitment of innate immune cells. By leveraging monoclonal antibodies, Thabor Therapeutics seeks to provide effective solutions for healthcare providers to treat patients suffering from these conditions.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with research facilities in Nice. Founded in 2019, it specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of both Type 1 and Type 2 diabetes. The company aims to create a candidate molecule that regenerates pancreatic insulin-producing cells, which could significantly improve the quality of life and survival rates for individuals with diabetes. This innovative approach has the potential to become a groundbreaking therapy for beta-cell regeneration in diabetes management, stemming from research conducted in the laboratory of Dr. Patrick Collombat.

Wellium SAS is a company focused on digital transformation in the medical sector, founded in 2016 and located in Levallois-Perret, France. It specializes in teleconsultation solutions, providing tools that facilitate online consultations between doctors and patients. One of its key offerings is Feelae, an application designed to address issues such as medical desertification and overcrowding in emergency services by enabling patients to receive care remotely. Additionally, Wellium provides Leah, a teleconsultation solution tailored specifically for medical professionals. Through these services, Wellium aims to enhance accessibility and efficiency in healthcare delivery.

Alderaan Biotechnology is a biotechnology company focused on developing innovative antibodies aimed at treating cancer. The company specializes in monoclonal antibodies that target specific immune cells, particularly Natural Killer (NK) cells and regulatory T (Treg) cells within the tumor microenvironment. These antibodies are designed to deplete Treg cells and enhance the cytotoxic activity of NK cells, representing a novel approach in immuno-oncology. By providing new immunotherapy options, Alderaan Biotechnology enables physicians to better address the complexities of cancer treatment through targeted immune modulation.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Urania Therapeutics is a biopharmaceutical company focused on the identification and development of readthrough compounds aimed at treating genetic diseases and certain cancers. The company utilizes a proprietary structure-based drug design platform to create novel therapeutic treatments that address conditions caused by mutations, specifically those involving premature stop codons during protein synthesis. By enabling the production of full-length, functional proteins, Urania Therapeutics targets a range of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its innovative approach, the company seeks to restore normal protein production, offering potential new solutions for patients with these challenging genetic conditions.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at addressing auto-immune and inflammatory disorders. The company's primary product is a peptide designed to maintain a cluster of truncated CD31 molecules at the membrane, which helps moderate overactive immune responses without complete blockade. By facilitating improved treatment options for medical companies, Tridek-One seeks to enhance the quality of life for patients suffering from these conditions.

Yukin Therapeutics is a French biotechnology company specializing in the development of innovative therapeutic molecules, particularly kinase inhibitors targeting the NIK protein, which plays a crucial role in the progression of various cancers. The company has conducted studies demonstrating proof of concept in animal models, showcasing the potential of its proprietary molecules to alter the tumor microenvironment. This alteration enhances the immune system's ability to infiltrate and eliminate tumors, thereby improving the efficacy of existing cancer immunotherapies. Yukin Therapeutics is currently focused on identifying a first drug candidate to advance into clinical trials, with the aim of addressing multiple cancer types, including skin and pancreatic cancers.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Alderaan Biotechnology is a biotechnology company focused on developing innovative antibodies aimed at treating cancer. The company specializes in monoclonal antibodies that target specific immune cells, particularly Natural Killer (NK) cells and regulatory T (Treg) cells within the tumor microenvironment. These antibodies are designed to deplete Treg cells and enhance the cytotoxic activity of NK cells, representing a novel approach in immuno-oncology. By providing new immunotherapy options, Alderaan Biotechnology enables physicians to better address the complexities of cancer treatment through targeted immune modulation.